Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group (Q39874235)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 May 2010

Language	Label	Description	Also known as
English	Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group	scientific article published on 13 May 2010

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group (English)

1 reference

Europe PubMed Central

15 September 2017

0 references

Toshihide Yamashita

14

object named as

Toshihiko Yamashita

1 reference

Europe PubMed Central

15 September 2017

Hideki Mizunuma

18

object named as

Hideki Mizunuma

1 reference

Europe PubMed Central

15 September 2017

author name string

Masataka Shiraki

1

1 reference

Europe PubMed Central

15 September 2017

Tatsuhiko Kuroda

2

1 reference

Europe PubMed Central

15 September 2017

Nobuaki Miyakawa

3

1 reference

Europe PubMed Central

15 September 2017

Naohito Fujinawa

4

1 reference

Europe PubMed Central

15 September 2017

Kazumasa Tanzawa

5

1 reference

Europe PubMed Central

15 September 2017

Akiko Ishizuka

6

1 reference

Europe PubMed Central

15 September 2017

Shiro Tanaka

7

1 reference

Europe PubMed Central

15 September 2017

Yukari Tanaka

8

1 reference

Europe PubMed Central

15 September 2017

Takayuki Hosoi

9

1 reference

Europe PubMed Central

15 September 2017

Eiji Itoi

10

1 reference

Europe PubMed Central

15 September 2017

Shigeto Morimoto

11

1 reference

Europe PubMed Central

15 September 2017

Akira Itabashi

12

1 reference

Europe PubMed Central

15 September 2017

Toshitsugu Sugimoto

13

1 reference

Europe PubMed Central

15 September 2017

Itsuo Gorai

15

1 reference

Europe PubMed Central

15 September 2017

Satoshi Mori

16

1 reference

Europe PubMed Central

15 September 2017

Hideaki Kishimoto

17

1 reference

Europe PubMed Central

15 September 2017

Naoto Endo

19

1 reference

Europe PubMed Central

15 September 2017

Yoshiki Nishizawa

20

1 reference

Europe PubMed Central

15 September 2017

Kunio Takaoka

21

1 reference

Europe PubMed Central

15 September 2017

Yasuo Ohashi

22

1 reference

Europe PubMed Central

15 September 2017

Hiroaki Ohta

23

1 reference

Europe PubMed Central

15 September 2017

Masao Fukunaga

24

1 reference

Europe PubMed Central

15 September 2017

Toshitaka Nakamura

25

1 reference

Europe PubMed Central

15 September 2017

Hajime Orimo

26

1 reference

Europe PubMed Central

15 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 May 2010

1 reference

Europe PubMed Central

15 September 2017

Journal of Bone and Mineral Metabolism

1 reference

Europe PubMed Central

15 September 2017

29

1 reference

Europe PubMed Central

15 September 2017

1

1 reference

Europe PubMed Central

15 September 2017

37-43

1 reference

Europe PubMed Central

15 September 2017

https://scigraph.springernature.com/pub.10.1007/s00774-010-0188-x

0 references

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteopo

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Diagnostic criteria for primary osteoporosis: year 2000 revision

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Compliance with pharmacologic therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Fracture outcomes related to persistence and compliance with oral bisphosphonates

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence

1 reference

https://api.crossref.org/works/10.1007%2FS00774-010-0188-X

21 January 2018

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20461422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20461422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00774-010-0188-X

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39874235&oldid=2092674694"